Abstract: Heterobicyclic derivatives of the formula: wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

Abstract: Heterobicyclic derivatives of the formula: 1

Abstract: Heterobicyclic derivatives of the formula: wherein R1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alkyl which may have suitable substituent(s), R2 is aryl which may have suitable substituent(s) or heterocyclic group, and R3 is hydrogen, lower alkoxy or arylthio, and a pharmaceutically acceptable salt thereof which are useful as a medicament.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is pyridyl(lower)alkyl, N-oxidopyridyl(lower)alkyl or imidazolyl(lower)alkyl,R.sup.2 is aminophenyl, [protected amino]phenyl, [[[halophenyl](lower)alkenoyl]amino]phenyl, [[pyridyl(lower)alkenoyl]amino]phenyl, [[[N-oxidopyridyl](lower)alkenoyl]amino]phenyl, [[[protected aminopyridyl](lower)alkenoyl]amino]phenyl, [thiazolylcarbonylamino]phenyl which may have pyridyl, naphthyl having lower alkoxy and halogen, [dihalophenyl](lower)alkenyl, [N-oxidopyridyl](lower)alkenyl, [aminopyridyl](lower)alkenyl, [protected aminopyridyl](lower)alkenyl, [carboxypyridyl](lower)alkenyl, [protected carboxypyridyl](lower)alkenyl, [[pyridyl(lower)alkenyl]pyridyl](lower)alkenyl, [[carboxy(lower)alkenyl]pyridyl](lower)alkenyl, [[protected carboxy(lower)alkenyl]pyridyl](lower)alkenyl, [pyridyl(lower)alkenyl]pyridyl, lower alkylbenzothiazolyl or [halopyridylcarbonyl]amino,with proviso that when R.sup.

Abstract: This invention relates to certain 1-heterocycloalkylquinazolin-2,3-dione derivatives, certain pharmaceutically acceptable salts thereof, the process of making those compounds, and the method of using the compounds. The compounds and compositions display effects on the peripheral or central nervous system.

Abstract: A compound of the formula: ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, halogen, nitro, amino, protected amino, hydroxyamino, lower alkyl, hydroxy, protected hydroxy, sulfamoyl, carboxy, protected carboxy, mercapto, optionally substituted heterocyclic-carbonyl, optionally substituted heterocyclic-(lower)alkyl, lower alkylthio, hydroxy(lower)alkyl or protected hydroxy(lower)alkyl,R.sup.3 is aryl which may have suitable substituent(s), andA is lower alkylene,or pharmaceutically acceptable salts thereof.

Abstract: Compounds of the formula: ##STR1## are described wherein R.sup.1, R.sup.2, R.sup.3 and A are described in the claims. These compounds show significant dopamine receptor agonist activity.

Abstract: Diseases caused by platelet activating factor are prevented and treated by administration to a subject of a therapeutically effective amount of a piperazine compound of the formula: ##STR1## wherein R.sup.1 to R.sup.4 are as defined in the specification.

Abstract: The invention relates to a PAF-antagonist pharmaceutical composition comprising a compound of the formula: ##STR1## wherein R.sup.1 is pyridyl(lower)alkyl or thiazolyl(lower)alkyl,R.sup.2 is N-lower alkylindolyl(lower)alkyl which may have lower alkyl or halogen on the indole ring, andR.sup.3 and R.sup.4 are each hydrogen or lower alkyl; or pharmaceutically acceptable salt thereof.

Abstract: New semicarbazide derivatives of the formula: ##STR1## wherein R.sup.1 is hydrogen,R.sup.2 is hydrogen, lower alkyl, ar(lower)alkyl, lower alkenyl or aryl,R.sup.3 is lower alkyl, ar(lower)alkyl, lower alkenyl or aryl, orR.sup.2 and R.sup.3 are taken together to form (C.sub.2 -C.sub.6)alkylidene group optionally substituted with aryl or taken together with the adjacent nitrogen atom to form a saturated or unsaturated, 5- or 6-membered heterocyclic group optionally substituted with aryl; orR.sup.1 and R.sup.2 are taken together with the adjacent nitrogen atoms to form a saturated or unsaturated, 5- or 6-membered heterocyclic group or 1,2-diazaspiroalkane-1,2-diyl group,R.sup.3 is hydrogen, lower alkyl, ar(lower)alkyl, lower alkenyl or aryl;R.sup.4 is aryl which may have substituent(s) selected from lower alkyl, halogen, lower alkoxy, lower alkylamino, halo(lower)alkyl, hydroxy, lower alkanoyl, esterified carboxy and carboxy,R.sup.

Abstract: A compound of the formula: ##STR1## wherein R.sup.1 is hydrogen,R.sup.2 is hydrogen, lower alkyl, ar(lower)alkyl, lower alkenyl or aryl,R.sup.3 is lower alkyl, ar(lower)alkyl, lower alkenyl or aryl, orR.sup.2 and R.sup.3 are taken together to form (C.sub.2 -C.sub.6)-alkylidene group optionally substituted with aryl or taken together with the attached nitrogen atom to form a saturated or unsaturated, 5- or 6-membered heterocyclic group optionally substituted with aryl or lower alkyl; orR.sup.1 and R.sup.2 are taken together with the attached nitrogen atoms to form a saturated or unsaturated, 5- or 6-membered heterocyclic group or 1,2-diazaspiroalkane-1,2-diyl group,R.sup.3 is hydrogen, lower alkyl, ar(lower)alkyl, lower alkenyl or aryl;R.sup.4 is lower alkyl optionally substituted with di(lower)alkylamino or a heterocyclic group, or a heterocyclic group optionally having suitable substituent(s),R.sup.

Abstract: New phospholipid derivatives represented by the formula: ##STR1## wherein R.sup.1 is alkyl, alkoxy, alkylthio or alkylsulfonyl;R.sup.2 is hydrogen, hydroxy, alkoxy, lower alkanoyloxy or lower alkylcarbamoyloxy;n is 0 or 1;R.sup.3 is hydroxy or protected hydroxy; andR.sup.4 is lower alkoxy or lower alicyclic-oxy group which is substituted with 2 or more hydroxy or protected hydroxy groups, and may be substituted with lower alkoxy or another alicyclic-oxy group having two or more hydroxy or protected hydroxy groups, in which the alicyclic ring may contain an oxygen atom;and pharmaceutically acceptable salt thereof, which exhibit antitumor activity.

Abstract: New phospholipid derivatives represented by the formula: ##STR1## wherein R.sup.1 is alkyl, alkoxy or alkanoylamino;R.sup.2 is lower alkyl, lower alkanesulfonyl or arenesulfonyl;R.sup.3, R.sup.4 and R.sup.5 are each lower alkyl;n is 0 or 1A is lower alkylene optionally interrupted by a --NHCO-- group; andQ is oxido or lower alkoxy;provided that n is 0 or A is lower alkylene interrupted by a --NHCO-- group, or Q is lower alkoxy, when R.sup.1 is alkoxy and R.sup.2 is lower alkyl; and pharmaceutically acceptable salts thereof, which exhibit antitumor activity.

Abstract: New phospholipid derivatives represented by the formula: ##STR1## wherein R.sup.1 is alkyl, alkoxy, alkylthio, ar(lower)alkoxy or alkanoylamino; R.sup.2 is lower alkyl or ar(lower)alkyl; n is an integer of 0 or 1; A is lower alkylene; R.sup.3 is pyridinio or a group of the formula: ##STR2## in which R.sup.5, R.sup.6 and R.sup.7 are each hydrogen or lower alkyl; and R.sup.4 is hydrogen or lower alkyl; and pharmaceutically acceptable salt thereof, which exhibit anti-hypertensive activity.

Abstract: New phosphate derivatives represented by the formula: ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are each hydroxy, alkoxy, alkanoylamino or protected hydroxy;A is lower alkylene;R.sup.4 is alkylammonio, cyclic ammonio or cyclic amino; andR.sup.5 is oxido anion or hydroxy;and pharmaceutically acceptable salt thereof, which exhibit antitumor activity.